Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer
This trial is active, not recruiting.
|Treatments||blood test, questionnaire|
|Sponsor||Memorial Sloan Kettering Cancer Center|
|Collaborator||Sarah Lawrence College|
|Start date||March 1997|
|End date||December 2017|
|Trial size||5600 participants|
|Trial identifier||NCT00590109, 97-029, CA08748|
The purpose of this project is to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles (BRACA1 185delAG and 5382insC; BRCA2 6174delT) among Jewish women.
to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles among Jewish women.
time frame: Conclusion of the study
Female participants at least 19 years old.
Inclusion Criteria: - Patients are eligible for the study if they are over 18 years of age, identify their ancestry as Jewish (both Sephardic and Ashkenazi Jews are eligible), have or have had a diagnosis of breast cancer, and are able to give informed consent. - Relatives, age 18 or older, of the patients who meet eligibility criteria above and are found to have a specific BRCA1 or BRCA2 mutation if they are able to give informed consent.
|Official title||Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer|
|Principal investigator||Kenneth Offit, MD|
Call for more information